Dylan W Maixner1, Xisheng Yan, Mei Gao, Ruchi Yadav, Han-Rong Weng. 1. From the Department of Pharmaceutical and Biomedical Sciences, University of Georgia College of Pharmacy, Athens, Georgia (D.W.M., X.Y., M.G., R.Y., H.-R.W.); and Department of Cardiovascular Medicine, The Third Hospital of Wuhan, Wuhan, Hubei Province, China (X.Y.).
Abstract
BACKGROUND: Neuroinflammation and dysfunctional glial glutamate transporters (GTs) in the spinal dorsal horn are implicated in the genesis of neuropathic pain. The authors determined whether adenosine monophosphate-activated protein kinase (AMPK) in the spinal dorsal horn regulates these processes in rodents with neuropathic pain. METHODS: Hind paw withdrawal responses to radiant heat and mechanical stimuli were used to assess nociceptive behaviors. Spinal markers related to neuroinflammation and glial GTs were determined by Western blotting. AMPK activities were manipulated pharmacologically and genetically. Regulation of glial GTs was determined by measuring protein expression and activities of glial GTs. RESULTS: AMPK activities were reduced in the spinal dorsal horn of rats (n = 5) with thermal hyperalgesia induced by nerve injury, which were accompanied with the activation of astrocytes, increased production of interleukin-1β and activities of glycogen synthase kinase 3β, and suppressed protein expression of glial glutamate transporter-1. Thermal hyperalgesia was reversed by spinal activation of AMPK in neuropathic rats (n = 10) and induced by inhibiting spinal AMPK in naive rats (n = 7 to 8). Spinal AMPKα knockdown (n = 6) and AMPKα1 conditional knockout (n = 6) induced thermal hyperalgesia and mechanical allodynia. These genetic alterations mimicked the changes of molecular markers induced by nerve injury. Pharmacological activation of AMPK enhanced glial GT activity in mice with neuropathic pain (n = 8) and attenuated glial glutamate transporter-1 internalization induced by interleukin-1β (n = 4). CONCLUSIONS: These findings suggest that enhancing spinal AMPK activities could be an effective approach for the treatment of neuropathic pain.
BACKGROUND:Neuroinflammation and dysfunctional glial glutamate transporters (GTs) in the spinal dorsal horn are implicated in the genesis of neuropathic pain. The authors determined whether adenosine monophosphate-activated protein kinase (AMPK) in the spinal dorsal horn regulates these processes in rodents with neuropathic pain. METHODS: Hind paw withdrawal responses to radiant heat and mechanical stimuli were used to assess nociceptive behaviors. Spinal markers related to neuroinflammation and glial GTs were determined by Western blotting. AMPK activities were manipulated pharmacologically and genetically. Regulation of glial GTs was determined by measuring protein expression and activities of glial GTs. RESULTS:AMPK activities were reduced in the spinal dorsal horn of rats (n = 5) with thermal hyperalgesia induced by nerve injury, which were accompanied with the activation of astrocytes, increased production of interleukin-1β and activities of glycogen synthase kinase 3β, and suppressed protein expression of glial glutamate transporter-1. Thermal hyperalgesia was reversed by spinal activation of AMPK in neuropathicrats (n = 10) and induced by inhibiting spinal AMPK in naive rats (n = 7 to 8). Spinal AMPKα knockdown (n = 6) and AMPKα1 conditional knockout (n = 6) induced thermal hyperalgesia and mechanical allodynia. These genetic alterations mimicked the changes of molecular markers induced by nerve injury. Pharmacological activation of AMPK enhanced glial GT activity in mice with neuropathic pain (n = 8) and attenuated glial glutamate transporter-1 internalization induced by interleukin-1β (n = 4). CONCLUSIONS: These findings suggest that enhancing spinal AMPK activities could be an effective approach for the treatment of neuropathic pain.
Authors: Han-Rong Weng; Natarajan Aravindan; Juan P Cata; Jing-Hong Chen; Andrew D S Shaw; Patrick M Dougherty Journal: Neurosci Lett Date: 2005-09-23 Impact factor: 3.046
Authors: Adriana Medina; Sharon Burke; Robert C Thompson; William Bunney; Richard M Myers; Alan Schatzberg; Huda Akil; Stanley J Watson Journal: J Psychiatr Res Date: 2013-05-24 Impact factor: 4.791
Authors: Otto Quintus Russe; Christine V Möser; Katharina L Kynast; Tanya S King; Heike Stephan; Gerd Geisslinger; Ellen Niederberger Journal: J Pain Date: 2013-07-31 Impact factor: 5.820
Authors: Jun Hee Lee; Andrei V Budanov; Saswata Talukdar; Eek Joong Park; Hae Li Park; Hwan-Woo Park; Gautam Bandyopadhyay; Ning Li; Mariam Aghajan; Insook Jang; Amber M Wolfe; Guy A Perkins; Mark H Ellisman; Ethan Bier; Miriam Scadeng; Marc Foretz; Benoit Viollet; Jerrold Olefsky; Michael Karin Journal: Cell Metab Date: 2012-09-05 Impact factor: 27.287
Authors: Marina N Asiedu; Chongyang Han; Sulayman D Dib-Hajj; Stephen G Waxman; Theodore J Price; Gregory Dussor Journal: PLoS One Date: 2017-01-24 Impact factor: 3.240
Authors: Rory Mitchell; Graham Campbell; Marta Mikolajczak; Katie McGill; Don Mahad; Sue M Fleetwood-Walker Journal: Mol Neurobiol Date: 2019-01-28 Impact factor: 5.590